Published in Neuron on February 01, 1995
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell (2012) 3.39
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci U S A (2008) 2.68
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain (2015) 2.32
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One (2011) 2.19
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
The toxicity in vitro of beta-amyloid protein. Biochem J (1995) 2.17
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J Mol Biol (2009) 2.14
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J (2010) 2.12
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med (2014) 1.85
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84
αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A (2010) 1.83
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A (2001) 1.80
Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci (2001) 1.77
Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys J (2010) 1.71
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol (2015) 1.66
Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol (1999) 1.65
The synucleins. Genome Biol (2001) 1.65
The function of α-synuclein. Neuron (2013) 1.63
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener (2012) 1.63
Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.60
alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J (2004) 1.54
Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta (2008) 1.51
Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci (2010) 1.49
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell (2008) 1.48
Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol (2007) 1.43
Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci (2005) 1.41
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. Protein Sci (2001) 1.40
α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A (2014) 1.39
Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons. J Cell Biol (2004) 1.39
Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci (2008) 1.32
NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A (1995) 1.32
Alpha-synuclein populates both elongated and broken helix states on small unilamellar vesicles. J Biol Chem (2011) 1.31
Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic (2008) 1.30
Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med (2015) 1.29
Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.29
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A (2013) 1.26
Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis (2012) 1.25
Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J (1999) 1.25
Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol (2007) 1.24
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol (1996) 1.23
Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol (2008) 1.23
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain (2012) 1.22
Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J Clin Neurol (2011) 1.21
Complex seizure disorder caused by Brunol4 deficiency in mice. PLoS Genet (2007) 1.21
Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) (2005) 1.20
alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcohol-preferring and -nonpreferring rats. Proc Natl Acad Sci U S A (2003) 1.18
Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci (2011) 1.18
α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci (2011) 1.16
Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol (2009) 1.15
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol (1999) 1.14
Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol (2011) 1.13
Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain (2010) 1.13
Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci (2014) 1.11
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci (2012) 1.10
Alpha-synuclein tertiary contact dynamics. J Phys Chem B (2007) 1.09
Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci (2003) 1.09
Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem J (1997) 1.09
Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res (2009) 1.08
ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther (2014) 1.08
The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol (2009) 1.08
Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. J Biol Chem (2012) 1.07
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol (2011) 1.06
Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem (2009) 1.06
The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein. PLoS One (2011) 1.06
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther (2013) 1.06
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol (2009) 1.04
Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. Protein Sci (2006) 1.04
E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem (2011) 1.03
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (2014) 1.03
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol (2014) 1.01
Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol (2011) 1.01
Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener (2013) 1.01
Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus. J Neurosci (2012) 1.01
Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. Mol Ther (2012) 1.00
Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry (2006) 1.00
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol (2014) 0.99
Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia (2014) 0.99
Definition of a molecular pathway mediating α-synuclein neurotoxicity. J Neurosci (2015) 0.99
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci (2004) 0.98
Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics (2007) 0.98
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology (1990) 3.79
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Atomic Control of the SrTiO3 Crystal Surface. Science (1994) 2.72
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Monoclonal antibody 7H6 reacts with a novel tight junction-associated protein distinct from ZO-1, cingulin and ZO-2. J Cell Biol (1993) 2.56
Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology (2002) 2.47
A gradient from stable to cyclic populations of Clethrionomys rufocanus in Hokkaido, Japan. Proc Biol Sci (1996) 2.41
Distribution of brain HIV load in AIDS. Brain Pathol (1998) 2.36
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol (1992) 2.21
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
Neocortical damage during HIV infection. Ann Neurol (1991) 2.15
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest (1992) 2.12
Phosphorylation-dependent subcellular translocation of a Ca2+/calmodulin-dependent protein kinase produces an autonomous enzyme in Aplysia neurons. J Cell Biol (1985) 2.09
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron (2001) 2.05
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature (1997) 1.99
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem (1995) 1.95
Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol (1994) 1.90
Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol (1999) 1.89
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 1.87
The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol (2001) 1.86
Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies. J Neuropathol Exp Neurol (1988) 1.82
Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol (2003) 1.81
Analysis of result variability from high-density oligonucleotide arrays comparing same-species and cross-species hybridizations. Biotechniques (2002) 1.80
Neuronal death and perinatal lethality in voltage-gated sodium channel alpha(II)-deficient mice. Biophys J (2000) 1.79
DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization. J Neurosci (2000) 1.77
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology (2004) 1.74
Rejection of renal allografts: specific immunologic suppression. Science (1968) 1.73
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med (2000) 1.71
Advances in Alzheimer's disease. FASEB J (1991) 1.69
Cytomegalovirus DNA in the sera of patients with cytomegalovirus pneumonia. Br J Haematol (1991) 1.68
Hepatic resection for metastatic cancer. Am J Surg (1967) 1.66
Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol (1995) 1.66
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology (1996) 1.64
Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res (1994) 1.58
Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 1.58
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology (1997) 1.58
Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol (1999) 1.56
Structure-function relationships of the mouse inositol 1,4,5-trisphosphate receptor. Proc Natl Acad Sci U S A (1991) 1.55
Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res (2001) 1.53
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol (1992) 1.51
Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res (2008) 1.50
Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport (1999) 1.49
Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol (1995) 1.47
Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A (1997) 1.46
Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein. Science (1988) 1.46
Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A (1998) 1.45
Tumor invasion of the chest wall in lung cancer: diagnosis with US. Radiology (1993) 1.43
Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol (1999) 1.43
Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc Natl Acad Sci U S A (1994) 1.43
Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol (1997) 1.42
Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology (1995) 1.42
The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron (1989) 1.41
Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse (2007) 1.41
Urinary erythrocyte volume analysis: a simple method for localizing the site of hematuria in pediatric patients. J Pediatr (1989) 1.41
Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology (1999) 1.41
The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem (1995) 1.40
Subunits of RNA polymerase in function and structure. IX. Regulation of RNA polymerase activity by stringent starvation protein (SSP). J Mol Biol (1979) 1.39
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. Arch Pathol Lab Med (1999) 1.39
Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol (2000) 1.39
Advantages of immunostaining over DNA analysis using PCR amplification to detect p53 abnormality in long-term formalin-fixed tissues of human colorectal carcinomas. J Gastroenterol (1998) 1.39
Two sisters with clinical diagnosis of Wiskott-Aldrich syndrome: is the condition in the family autosomal recessive? Am J Med Genet (1995) 1.38
Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res (1998) 1.38
NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (2000) 1.36
Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn (1996) 1.36
The shifting patterns of HIV encephalitis neuropathology. Neurotox Res (2005) 1.36
Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol (1999) 1.36
Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol (2000) 1.36
Characterization of an amyloid beta precursor protein that binds heparin and contains tyrosine sulfate. Proc Natl Acad Sci U S A (1989) 1.36
Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry (1995) 1.35
Hippocampal sclerosis contributes to dementia in the elderly. Neurology (1997) 1.34
Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res (2001) 1.34
Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol (1993) 1.33
Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest (1998) 1.32
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience (2006) 1.32
NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci U S A (1995) 1.32
Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (1998) 1.31
Impaired postnatal development of hippocampal dentate gyrus in Sp4 null mutant mice. Genes Brain Behav (2006) 1.28
Detection of borna disease virus antigen and RNA in human autopsy brain samples from neuropsychiatric patients. Virology (1996) 1.27
Biosynthesis of RNA polymerase in Escherichia coli. IX. Growth-dependent variations in the synthesis rate, content and distribution of RNA polymerase. Mol Gen Genet (1979) 1.26